Showing 301 - 320 results of 492 for search '"Hepatitis C"', query time: 0.06s Refine Results
  1. 301

    The Efficacy of On-Site Integration Screening and Microelimination Programs for Chronic Hepatitis C in a Detection Center: A Comparison of the Treatment Outcomes and Characteristics of Incarcerated Patients and Outpatients by Hsuan-Yuan Chang, Su-Hung Wang, Hsing-Tao Kuo, Ming-Jen Sheu, I-Che Feng, Chung-Han Ho, Jui-Yi Chen, Chi-Shu Sun, Chi-Hsing Chen, Cheng-Yi Lin, Chun-Chi Yang

    Published 2024-01-01
    “…We aimed to analyze the different patient characteristics and treatment outcomes (such as sustained viral response, SVR) between incarcerated patients with chronic hepatitis C (CHC) and those with CHC from the outpatient department through an on-site integrated screening and microelimination program in a detection center. …”
    Get full text
    Article
  2. 302

    Treatment of Chronic Hepatitis C Infection among Current And Former Injection Drug Users within a Multidisciplinary Treatment Model at a Community Health Centre by Adam I Newman, Shelley Beckstead, David Beking, Susan Finch, Tina Knorr, Carol Lynch, Meredith MacKenzie, Daphne Mayer, Brenda Melles, Ron Shore

    Published 2013-01-01
    “…The aim of the present prospective observational study was to assess uptake and success of hepatitis C virus (HCV) treatment among a group of former and current injection drug users with chronic HCV infection at the Street Health Centre in Kingston, Ontario. …”
    Get full text
    Article
  3. 303
  4. 304
  5. 305

    Combined Liver Stiffness and Α-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C by Sheng-Hung Chen, Hsueh-Chou Lai, Wen-Pang Su, Jung-Ta Kao, Po-Heng Chuang, Wei-Fan Hsu, Hung-Wei Wang, Tsung-Lin Hsieh, Hung-Yao Chen, Cheng-Yuan Peng

    Published 2022-01-01
    “…Long-term risk stratification using combined liver stiffness (LS) and clinically relevant blood tests acquired at the baseline further beyond the sustained virologic response (SVR) visit for chronic hepatitis C (CHC) has not been thoroughly investigated. …”
    Get full text
    Article
  6. 306
  7. 307
  8. 308
  9. 309
  10. 310

    Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis by Liwei Zhuang, Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Huichun Xing, Huichun Xing

    Published 2025-02-01
    “…IntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilaprevir (VOX), and glecaprevir (GLE) + pibrentasvir (PIB) in treating patients infected with HCV GT3 in a real-world setting.MethodsUsing the EMBASE, PubMed, and Cochrane Library databases, articles were screened from 1 January 2016 to 1 June 2024. …”
    Get full text
    Article
  11. 311
  12. 312

    Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy by Eric M Yoshida, Morris Sherman, Vincent G Bain, Curtis L Cooper, Marc Deschênes, Paul J Marotta, Samuel S Lee, Mel Krajden, Helga Witt-Sullivan, Robert J Bailey, Christopher Usaty, Kevork Peltekian, the Canadian Pegasys Study Group

    Published 2009-01-01
    “…BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.…”
    Get full text
    Article
  13. 313

    Hepatitis C Virus Seroconversion among Hiv-Positive Men Who Have Sex with Men with No History of Injection Drug Use: Results from a Clinical Hiv Cohort by Ann N Burchell, Sandra L Gardner, Tony Mazzulli, Michael Manno, Janet Raboud, Vanessa G Allen, Ahmed M Bayoumi, Rupert Kaul, Frank McGee, Peggy Millson, Robert S Remis, Wendy Wobeser, Curtis Cooper, Sean B Rourke

    Published 2015-01-01
    “…BACKGROUND: Internationally, there is a growing recognition that hepatitis C virus (HCV) may be sexually transmitted among HIV-positive men who have sex with men (MSM).…”
    Get full text
    Article
  14. 314

    Modelling the potential clinical and economic impact of universal antenatal hepatitis C (HCV) screening and providing treatment for pregnant women with HCV and their infants in Egypt: a cost-effectiveness study by Giuseppe Indolfi, Diana M Gibb, Aya Mostafa, Sarah Pett, Yazdan Yazdanpanah, Sylvie Deuffic-Burban, Anthony E Ades, Karen Scott, Ali Judd, Nadia Hachicha-Maalej, Clotilde Lepers, Intira Jeannie Collins, Manal H El Sayed

    Published 2024-04-01
    “…Backgrounds and aims Pregnant women and children are not included in Egypt’s hepatitis C virus (HCV) elimination programmes. This study assesses the cost-effectiveness of several screening and treatment strategies for pregnant women and infants in Egypt.Design A Markov model was developed to simulate the cascade of care and HCV disease progression among pregnant women and their infants according to different screening and treatment strategies, which included: targeted versus universal antenatal screening; treatment of women in pregnancy or deferred till after breast feeding; treatment of infected children at 3 years vs 12 years. …”
    Get full text
    Article
  15. 315
  16. 316
  17. 317

    Antidepressant Prophylaxis Reduces Depression Risk but Does Not Improve Sustained Virological Response in Hepatitis C Patients Receiving Interferon Without Depression at Baseline: A Systematic Review and Meta-Analysis by Awad Al-Omari, Juthaporn Cowan, Lucy Turner, Curtis Cooper

    Published 2013-01-01
    “…BACKGROUND: Depression complicates interferon-based hepatitis C virus (HCV) antiviral therapy in 10% to 40% of cases, and diminishes patient well-being and ability to complete a full course of therapy. …”
    Get full text
    Article
  18. 318
  19. 319
  20. 320